Ovarian cancer kills approximately 750 Australian women each year. Response to chemotherapy varies widely – a few patients will be cured, most will respond initially but eventually relapse, and about one third will progress while on treatment.
The purpose of this project is to find genes that influence a woman’s response to chemotherapy. This could identify patients who are now exposed to the toxic effects of chemotherapy without significant benefit and allow selection of better chemotherapy.
We are carrying out a genome-wide association study in a large set of patients from Australia (Australian Ovarian Cancer Study) and internationally (Ovarian Cancer Association Consortium). This study aims to identify specific variants influencing progression free survival (chemotherapy response).